Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
By W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Dávalos, D. Guidetti, V. Larrue, K. Lees, Z. Medeghri, T. Machnig and 4 more. New England Journal of Medicine, 2008
6,056 citations recorded by the source corpus.
Subfields: Epidemiology, Neurology, Rehabilitation
View Paper: https://www.semanticscholar.org/paper/7755e0ab0adb14ffe3a7260efa85e40013337fbc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Neurology
Citations in the corpus
- Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association (2013, methodology): “008).(169) However, mortality in the 2 treatment groups did not differ significantly and was nominally higher among the subjects treated with placebo.”
- Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “Symptomatic intraparenchymal hemorrhage remains a devastating complication of thrombolytic therapy with hematoma expansion occurring in up to 40 % of patients and mortality rates ranging from 9 to 61 % at 3 months [325, 348–350].”
- Factors Influencing the Decline in Stroke Mortality (2013, methodology): “treatment with intravenous tPA prevents poststroke death, although it does prevent poststroke disability.(330,331) In a pooled by gest on A uust 3, 2017 http://strhajournals.”
- The Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials (2017, methodology): “Such trials include PROACT II, TREVO 2 (Thrombectomy REvascularization of Large Vessel Occlusions), REVASCAT, THRACE, and ECASS III (European Cooperative Acute Stroke Study).(13,40,41,45,46) These trials illustrate that dichotomous approaches to the mRS can be statistically significant when ordinal ”
- Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. (2019, background): “tor (rtPA), which dissolves the clot to restore blood flow (73).”